Obesity and Dyslipidemia.

IF 5.7 2区医学 Q1 PERIPHERAL VASCULAR DISEASE

Current Atherosclerosis Reports Pub Date : 2023-12-01 Epub Date: 2023-11-18 DOI:10.1007/s11883-023-01167-2

Barbora Nussbaumerova, Hana Rosolova

{"title":"Obesity and Dyslipidemia.","authors":"Barbora Nussbaumerova, Hana Rosolova","doi":"10.1007/s11883-023-01167-2","DOIUrl":null,"url":null,"abstract":"Purpose of review: This article sumarizes pathopysiological consequencies between obesity and dyslipidemia and aims to bring some practical approach.Recent findings: Dyslipidemia is often present in individuals with obesity and simultaneusly, many obese individuals have lipid metabolism disorders. Especially the abdominal obesity increases the cardiometabolic risk because of the presence of atherogenic dyslipidemia while the total low density lipoprotein cholesterol (LDL-C) may be normal. LDL-C is the primary goal in dyslipidemia treatment. Apoliprotein B (Apo B) and non - high density lipoprotein cholesterol (non-HDL-C) should be estimated to precise the cardiovascular risk and represents the secondary goal in treatment. Weight loss either with diet or antiobestic medication induces the decrease in triglycerides (TG) and LDL-C and the increase in HDL-C. Composition of nutrients, esp. fatty acids, influences lipid levels. Bariatric surgery is efficient in weight loss and has a significant effect on serum lipids. Dyslipidemia and obesity present common diseases that must be managed to decrease the cardiovascular risk and the risk of obesity-related complications.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":" ","pages":"947-955"},"PeriodicalIF":5.7000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Atherosclerosis Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11883-023-01167-2","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/18 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: This article sumarizes pathopysiological consequencies between obesity and dyslipidemia and aims to bring some practical approach.

Recent findings: Dyslipidemia is often present in individuals with obesity and simultaneusly, many obese individuals have lipid metabolism disorders. Especially the abdominal obesity increases the cardiometabolic risk because of the presence of atherogenic dyslipidemia while the total low density lipoprotein cholesterol (LDL-C) may be normal. LDL-C is the primary goal in dyslipidemia treatment. Apoliprotein B (Apo B) and non - high density lipoprotein cholesterol (non-HDL-C) should be estimated to precise the cardiovascular risk and represents the secondary goal in treatment. Weight loss either with diet or antiobestic medication induces the decrease in triglycerides (TG) and LDL-C and the increase in HDL-C. Composition of nutrients, esp. fatty acids, influences lipid levels. Bariatric surgery is efficient in weight loss and has a significant effect on serum lipids. Dyslipidemia and obesity present common diseases that must be managed to decrease the cardiovascular risk and the risk of obesity-related complications.

查看原文本刊更多论文

肥胖和血脂异常。

综述目的:本文综述了肥胖与血脂异常之间的病理生理关系，旨在提出一些实用的方法。最近的研究发现:血脂异常通常存在于肥胖人群中，同时，许多肥胖人群存在脂质代谢紊乱。特别是腹部肥胖由于存在致动脉粥样硬化性血脂异常而增加心脏代谢风险，而总低密度脂蛋白胆固醇(LDL-C)可能是正常的。LDL-C是治疗血脂异常的主要目标。应估计载脂蛋白B (Apo B)和非高密度脂蛋白胆固醇(non- hdl - c)以精确心血管风险，并代表治疗的次要目标。通过饮食或抗肥胖药物减轻体重可导致甘油三酯(TG)和LDL-C的降低以及HDL-C的增加。营养成分，特别是脂肪酸，影响脂质水平。减肥手术在减肥方面是有效的，对血脂有显著的影响。血脂异常和肥胖是常见病，必须加以控制，以降低心血管风险和肥胖相关并发症的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Atherosclerosis Reports 医学-

CiteScore

9.00

自引率

3.40%

发文量

审稿时长

6-12 weeks

期刊介绍： The aim of this journal is to systematically provide expert views on current basic science and clinical advances in the field of atherosclerosis and highlight the most important developments likely to transform the field of cardiovascular prevention, diagnosis, and treatment. We accomplish this aim by appointing major authorities to serve as Section Editors who select leading experts from around the world to provide definitive reviews on key topics and papers published in the past year. We also provide supplementary reviews and commentaries from well-known figures in the field. An Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research.